Contact:
Newsfox Desk
Phone: + 43 - 1 - 811 40 - 319
E-Mail: editor@newsfox.com
| Pressbox | 
|
Leverkusen (pte042/21.05.2003/17:23) - Pharmaceutical group Bayer http://www.bayer.de is bringing cannabis-based medication onto the market. The group located in Leverkusen has signed an agreement with GW Pharmaceuticals plc (GW) http://www.gwpharm.com for the exclusive distribution of Sativex, a cannabis-based spray for the treatment of symptoms of multiple sclerosis (MS).
Sativex can also be used to treat severe neuropathic pain. Bayer's marketing of the product will first be limited to Great Britain, as both companies announced today. Bayer has also secured the option to negotiate distribution rights in other European countries.
According to GW, Sativex consists of pure cannabis plant extract whose main ingredients are tetrabinex (tetrahydrocannabinol - THC) and nabidiolex (cannabidiol - CBD). It is administered as an oral spray. The medication is also in the third phase of approval for cancer treatment.
(end)
|
|
